Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edifoligide for PTFE Vascular Access Graft Patency
NCT00086164Phase 2Terminated
- Sponsor
- Anesiva
- Start
- May 2004
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of edifoligide in neointimal hyperplasia (NIH) and vascular graft stenosis (3 arms), sponsored by Anesiva. Primary endpoints: Graft/Recipient Vein Stenosis at 6 months and Preservation of Graft Function at 6 months. Started May 2004; status: terminated.
02
Drugs
edifoligide
03
Conditions
neointimal hyperplasia (NIH)vascular graft stenosis
Beyond the preview
Go deeper on NCT00086164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086164.